Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

56.09
+1.793.30%
Post-market: 56.100.0100+0.02%18:18 EDT
Volume:3.20M
Turnover:175.13M
Market Cap:8.59B
PE:20.26
High:56.27
Open:53.00
Low:52.11
Close:54.30
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:2.34
T/O Rate:2.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:14.21
PE(LYR):20.25

Loading ...

TG Therapeutics Price Target Maintained with a $78.00/Share by HC Wainwright & Co.

Dow Jones
·
5 hours ago

Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET) and TG Therapeutics (TGTX)

TIPRANKS
·
7 hours ago

TG Therapeutics (TGTX) Tests A Key Moving Average, Is The Stock Fully Priced?

Simply Wall St.
·
Aug 25

TG Therapeutics Advances Injectable MS Therapy With New Phase 2 Device Study

TIPRANKS
·
Aug 22

Movement Alert|TG Therapeutics Rises 9.39% in Regular Trading, Trading at $55.29

Market Focus
·
Aug 22

TG Therapeutics rumor highlighted in Betaville blog

TIPRANKS
·
Aug 21

TG Therapeutics jumps 4% to $52.82 after Betaville mention

TIPRANKS
·
Aug 21

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

Simply Wall St.
·
Aug 16

TG Therapeutics (TGTX) Raised Revenue Guidance After Q2, Is It Still Below Fair Value?

Simply Wall St.
·
Aug 14

TG Therapeutics price target raised to $21 from $20 at BofA

TIPRANKS
·
Aug 06

TG Therapeutics (TGTX) Looks Fairly Valued After Raised 2026 Guidance And Mixed Q2 Earnings

Simply Wall St.
·
Aug 06

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Syndax Pharmaceuticals (SNDX) and DaVita (DVA)

TIPRANKS
·
Aug 05

TG Therapeutics Earnings Call Signals BRIUMVI Surge

TIPRANKS
·
Aug 05

Movement Alert|TG Therapeutics Rises 5.01% in Regular Trading, Rebounding as Market Re-Prices Q2 Revenue Beat and Raised Full-Year Guidance

Market Focus
·
Aug 05

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Switzerland's Crispr Therapeutics Q2 Casgevy Revenue Jumps 151%, Net Loss Narrows on FDA Approval for Expansion

Reuters
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04

TG Therapeutics Down over 11%, on Pace for Largest Percent Decrease Since August 2025

Dow Jones
·
Aug 04

TG Therapeutics falls -10.6%

TIPRANKS
·
Aug 04

Movement Alert|TG Therapeutics Falls 5.35% in Regular Trading, Q2 EPS Misses Estimates by 85%

Market Focus
·
Aug 03